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Abstract
Vestibular schwannomas (VSs) are benign, slow-growing tumors. Management options include observation, surgery, and 
radiation. In this retrospective trial, we aimed at evaluating whether biologically e!ective dose (BED) plays a role in tumor 
volume changes after single-fraction first intention stereotactic radiosurgery (SRS) for VS. We compiled a single-institution 
experience (n = 159, Lausanne University Hospital, Switzerland). The indication for SRS was decided after multidiscipli-
nary discussion. Only cases with minimum 3"years follow-up were included. The Koos grading, a reliable method for tumor 
classification was used. Radiosurgery was performed using Gamma Knife (GK) and a uniform marginal prescription dose 
of 12"Gy. Mean BED was 66.3"Gy (standard deviation 3.8, range 54.1–73.9). The mean follow-up period was 5.1"years 
(standard deviation 1.7, range 3–9.2). The primary outcome was changes in 3D volumes after SRS as function of BED and 
of integral dose received by the VS. Random-e!ect linear regression model showed that tumor volume significantly and 
linearly decreased over time with higher BED (p < 0.0001). Changes in tumor volume were also significantly associated 
with age, sex, number of isocenters, gradient index, and Koos grade. However, the e!ect of BED on tumor volume change 
was moderated by time after SRS and Koos grade. Lower integral doses received by the VSs were inversely correlated with 
BED in relationship with tumor volume changes (p < 0.0001). Six (3.4%) patients needed further intervention. For patients 
having uniformly received the same marginal dose prescription, higher BED linearly and significantly correlated with tumor 
volume changes after SRS for VSs. BED could represent a potential new treatment paradigm for patients with benign tumors, 
such as VSs, for attaining a desired radiobiological e!ect. This could further increase the e#cacy and decrease the toxicity 
of SRS not only in benign tumors but also in other SRS indications.
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Vestibular schwannomas (VSs) are rising from the 
Schwann cells, which usually wrap around motor and sen-
sory nerves and, for this particular case, the  VIII$th cra-
nial nerve [4]. Patients may experience di!erent specific 
symptoms, of whom most common is unilateral hearing 
loss, ringing in the ear (tinnitus), dizziness, facial numb-
ness (if compression of the trigeminal nerve), and rarely 
facial weakness (if major compression of facial nerve). 
The apparent increase in incidence has been considered 
related to increase of earlier diagnosis and incidental find-
ing on magnetic resonance imaging (MRI) [4].
It has been classically considered that VSs are slow-
growing tumors, with an average rate of 1"mm/year [23]. 
However, recent research suggests that the majority of 
VSs might experience volumetric growth, with about one-
third growing at a rate of 100% per year [27]. Management 
options include observation [22], microsurgical resection 
[19], or radiation [3, 14]. There is currently no consensus 
with regard to patient’s selection for therapeutic inter-
vention, although recent studies suggested radiosurgery 
(in contrast to observation) for small VSs in patients not 
choosing surgical resection [15]. The outcome goals for 
both patients and medical sta! are tumor control on long-
term basis, while preserving cranial nerve function and 
thus high quality of life.
Single-fraction stereotactic radiosurgery (SRS) is clas-
sically recommended for small to medium size VSs [14]. 
Rates of SRS tumor control are considered similar to those 
of microsurgical resection, while SRS being less invasive 
and achieve better preservation of cranial nerves, particu-
larly the facial and cochlear [24]. There was progressive 
marginal dose prescription de-escalation, to currently 
11–13"Gy [26], while attaining equivalent tumor control 
but with lower morbidity [14, 17]. Recent studies sug-
gested as only predictor for long-term tumor control the 
initial tumor volume, with 5-year tumor control rate of 
approximately 91% [13].
It is now well acknowledged that beam on time engaged 
to deliver same radiation dose may vary significantly. Par-
ticularly, for the case of VSs, using multiple isocenters and 
Gamma Knife (GK), this parameter might vary up by a fac-
tor of 10. This aspect is particularly due to decay of the 
Cobalt-60 sources, with a half-life of 5.26"years. The bio-
logically e!ective dose (BED), a concept initially used in 
fractionated radiotherapy, incorporates both the prescribed 
dose and treatment time [6]. In 1989, Fowler coined the term 
BED as a linear-quadratic (LQ)–based formula [5]. After 
21"years, the same author suggested the wide use of BED 
in the radiation therapies [6]. Moreover, BED was defined 
as “the total dose required to give the same log cell kill as 
the schedule being studied, at an infinitely low-dose rate or 
with infinitely small fractions well-spaced out, now with an 
overall time factor for repopulation during continued irra-
diation. Millar and Canney also proposed this methodology 
[20, 21]. More recently, application to single-fraction GK 
was described by Hopewell et"al. [9] and further assessed 
for the outcomes after GK for trigeminal neuralgia (playing 
a role in pain cessation and complication appearance) [28], 
for pituitary growth-hormone secreting tumors, the former in 
the context of decrease in hormone excessive secretion (e.g., 
in acromegaly, by playing a role in the biological remission) 
[8] or arteriovenous malformations (by playing a role in 
obliteration) [29]. However, little is known about the role of 
BED in tumor volume changes, while prescribing a uniform 
radiation dose in single-fraction SRS.
Here we investigated, for the first time, whether BED 
might play a role on long-term 3D tumor volume changes 
after single-fraction SRS for benign tumors, such as VSs.
Methods
Study design and!participants
In this retrospective, unicentric study, we analyzed 159 
consecutive VSs that have been treated with first intention, 
single-fraction SRS in Lausanne University Hospital, Swit-
zerland, treated between June 2010 (opening of our GK 
center) and October 2016.
Tumor control is evaluated on long-term basis after SRS, 
usually with a minimum follow-up of 2–3"years. In this 
sense, cases with less than 3"years follow-up were excluded 
from the present study.
The indication for treatment was always decided after 
multidisciplinary discussion. Inclusion criteria were as 
follows: patients aged of at least 18"years old at time of 
treatment, able to provide written informed consent, treated 
with first intention SRS for VSs. Were excluded patients 
with previous microsurgical resection (n = 58), pure intra-
cochlear and/or intravestibular (n = 4) tumors, cystic VS 
(reputed to have di!erent radiological answer, n = 4) [2], 
type II neurofibromatosis (n = 3), previous radiation (n = 1, 
failed Linac radiosurgery), or a prescribed dose of 11"Gy 
(n = 1, to have uniform dose prescription). Two patients were 
lost for follow-up. Eighty-five (53.4%) patients underwent 
single-fraction SRS because of volume increase on serial 
follow-up MRI, while 74 (46.6%) had either tumors already 
large at initial presentation (i.e., touching the brainstem) or 
small but stable tumors with serviceable hearing, assum-
ing that proactive treatment would increase their chances of 
maintaining functional hearing [25].
Demographic data can be found in Table"1.
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Koos grade [16] was used to characterize the size 
and anatomical relationship of the VSs. In our practice, 
we reserve SRS to small to medium size tumors; only 3 
patients with large tumors (i.e., Koos grade IV) had SRS, 
due to contraindication for surgery (n = 2) or patient’s 
choice (n = 1). Facial function was normal in all cases at 
the time of SRS (House-Brackmann grade 1) [10]. The 
Gardner-Robertson (GR) scale was used to classify hear-
ing function [7]. One hundred and nine (68.5%) patients 
had useful hearing before SRS (GR class 1 or 2, Table"1). 
Eighty-nine (81.6%) retained useful hearing at 3"years 
after SRS.
Radiosurgery treatment
All patients underwent single-fraction SRS by GK in the 
modern era of SRS, using completely automatized GK 
models, including Gamma Knife Perfexion (between June 
2010 and until June 2016) and ICON (starting June 2016, 
Elekta Instruments, AB, Sweden). After frame application 
under local anesthesia, all underwent multimodal stereo-
tactic imaging, including both MRI (T1-weighted with and 
without Gadolinium injection (1"mm slices with no gap) and 
T2 CISS/Fiesta (0.6"mm slices with no gap)) and computer 
tomography (CT).
Table 1  Basic demographic 
data Variable Mean (standard deviation, range)
Follow-up period 5.1"years (1.7, 3–9.2)
Minimum 3"years of follow-up: 159 (100%)
N patient 159
Age 58.5"years (13.1, 21.1–83.6)
Side Right: left = 78 (49.1%): 81 (51.9%)
Sex M: F = 72 (45.3%): 87 (54.7%)
Common presenting symptoms
  • Hypoacusia
  • Vertigo
  • Incidental
  • Tinnitus






Prior surgery 0 (0%)
Prior irradiation 0 (0%)
Koos grade
  • I
  • II
  • III





Maximal diameter 14.2"mm (5.5, 4–29.5)
Hearing at baseline (Gardner-Robertson class) • 1: 71 (44.6%)
• 2: 38 (23.9%)
• 3: 22 (13.8%)
• 4: 5 (3.1%)
• 5: 23 (14.5%)
Table 2  Basic dosimetric data 
at the time of radiosurgery Variable Mean (standard deviation, range)
Dose 12"Gy (100% of patients)
BED 66.3  Gy2.47 (3.8, 54.1–73.9)
Beam on time 40.7"min (17.7, 7.3–101.8)
Number of isocenter 9.7 (7.2, 1–32)
Radiation dose rate 2.7"Gy/min (0.6, 1.7–3.8)
Tumor volume 1.3"mL (1.5, 0.03–8.5)
Integral dose received by the tumor volume 18.7"mJ (23.2, range 0.2–116.6)
Maximal dose received by the cochlea 4.3"Gy (1.5, 1.5–10.5)
Gradient index 3 (0.5, 2.4–5.8)
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A marginal dose of 12"Gy was prescribed in all patients.
The dosimetric data can be seen in Table"2. The mean 
beam on time was 40.7"min (standard deviation (std dev) 
17.7, range 7.3–101.8). The mean tumor volume was 1.1"cc 
(std dev 1.4, range 0.01–7.8). The mean integral dose 
received by the tumor volume was 18.7"mJ (std dev 23.2, 
range 0.2–116.6).
There was no treatment interruption during the GK sin-
gle-fraction sessions.
Primary aim
The primary outcome was changes in 3D volumes after SRS 
as function of BED.
Biologically e"ective dose computation
The mean BED was 66.3"Gy (std dev 3.8, range 54.1–73.9). 
The BED was computed using the basic BED model, which 
takes into account the beam on time and the prescribed dose. 
Of note, all patients received the uniform marginal dose of 
12"Gy.
Biologically e!ective dose values were calculated using 
similar approaches, as proposed by Jones and Hopewell [12]. 
We have initially applied such calculations to monoisocen-
tric plans (trigeminal neuralgia) [28]. We further suggested 
that BED can be a better predictor as compared with the 
prescribed marginal dose for obliteration of arteriovenous 
malformations after single-fraction radiosurgery, using a 
uniform dose prescription [29]. Recently, we also evaluated 
the BED’s role in endocrine remission, in the context of GK 
for acromegaly [1].
Biologically e"ective dose analysis function 
of!primary outcome
The BED was analyzed as a continuous variable in relation-
ship with 3D volume changes (please see below). A second-
ary analysis was conducted using BED as by third quartiles.
Moreover, BED was analyzed as a continuous variable for 
the probability of progression at 3"years after SRS (a change 
in volume between therapeutic moment and 3"years after 
SRS of more than 0%, binary outcome—stable or decrease 
versus increased) but also for the probability of further surgi-
cal intervention.
Follow-up period and!protocol
The mean follow-up period was 5.1"years (std dev 1.7, range 
3–9.2). Fifty-three (33.3%) of cases had 5"years follow-up 
MRIs and 51 (32.1%) had 7 or 9"years follow-up MRIs.
The neurosurgery team (CT, ML) performed regular 
follow-up at 6, 12, 36, 60, 84, and 108"months, respectively. 
Each patient underwent brain MRI and, if pre-SRS useful 
hearing, audiologic assessment. All patients had been seen 
in person. The same scales as defined in the “Study design 
and participants” section were used during follow-up period.
Radiosurgery failure was defined as the need for addi-
tional treatment, with second SRS, microsurgery, or a com-
bination of both techniques. The main indication for such 
approach was tumor progression noted during consecutive 
measurements and potential symptomatic mass e!ect. The 
final decision whether to retreat a patient or not was made 
in multidisciplinary discussion.
Volumetric analysis
All volumes (3D) were measured within the Leksell Gamma 
Plan (LGP, Elekta Instruments, AB, Sweden) using a stand-
ardized procedure, by manual contouring, by the same neu-
rosurgeons (ML, CT). The T1-weighted Gadolinium injected 
(1"mm slice) image during follow-up was available for each 
patient and was co-registered with the therapeutic one. The 
automated segmentation tool from the LGP was used to con-
tour the VS on each slice, slice by slice, and corrected manu-
ally when appropriate (e.g., segmentation including non-VS 
contrast-enhancing structures, such as dura and vessels).
The volume was noted individually and at each time 
point, in milliliters (Fig."1a).
Statistical analysis
Statistical analysis was performed using Stata 14 (Stata-
Corp, College 109 Station, Texas). Descriptive statistics 
were related as proportion/frequency for categorical data 
and mean, median, and range for continuous variables. The 
therapeutic tumor volumes were log transformed to get a 
normal distributed outcome (Fig."1b). Random-e!ect linear 
model was then used to assess the association between the 
outcome, the time point after SRS (time, 3, 5, 7, or 9"years), 
the BED, and covariates of interest.
First, univariable associations were tested for each covari-
ate as well as their potential interactions.
Then, significant predictors at a 20% level were consid-
ered in a backward procedure selection to fit a multivariable 
model. Let Vij the tumor volume of the subject i measured 
at timeij and Xi be a covariate (like age, sex,…) or inter-
action between two covariates (like BED % Koos grade or 
BED % time) of subject i measured at Gamma Knife interven-
tion. The fitted random-e!ect linear model was:
where !0 is the global mean, !1 , !2 , and !x are the fixed 





+ !1Timeij + !2BEDi + !xXi + "ij
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of time, BED and covariate X on the tumor volume. The ui is 
the individual-specific random e!ect and !ij the independent 
measurement errors with mean zero.
To illustrate the dynamics of tumor volume decrease 
after SRS according to the BED value, we additionally 
coded the BED in three categories (1st, 2nd, 3rd quar-
tiles) and plotted the linear prediction by BED quartile 
over time.
Results
BED and!tumor volume decrease
The mean tumor volume at the time of SRS was 1.3"mL 
(std dev 1.5, range 0.03–8.5) (Table"3, Fig."1, c—for each 
individual patients at baseline and with the further vari-
ations during follow-up), at 3"years was 0.9"mL (std dev 
Fig. 1  The therapeutic tumor 
volumes were not normally 
distributed (Fig."1a); in this 
respect, a logarithmic transfor-
mation was done (Fig."1b ); the 
mean tumor volume at the time 
of SRS receiving the radia-
tion dose and during follow-up 
course (c for each individual 




1.3, range 0.01–10.7), at 5"years 0.7"mL (std dev 1.1, range 
0.03–6.4), and at more or equal to 7"years was 0.8 (std dev 
0.9, range 0.04–5.6, Fig."1, d—for all patients, censored 
at 7"years).
The univariate analysis showed that increasing 
the BED by one unit was associated with tumor vol-
ume decrease (log-scaled) of $ 0.27 (95% confidence 
interval (CI) [$ 0.31, $ 0.24], p < 0.0001) in average 
(Fig."2). Moreover, tumor volume decreased by a mean 
of $ 0.47 (95% CI [$ 0.55, $ 0.38], p < 0.0001), $ 0.55 
(95% CI [$ 0.68, $ 0.41], p < 0.0001), and $ 0.72 (95% 
CI [$ 0.87, $ 0.59], p < 0.0001) respectively at 3"years, 
5"years, and 7"years follow-up. Other covariates associ-
ated with tumor volume that decrease after SRS were age, 
Table 3  Vestibular schwannoma 
volumetric evolution after 
radiosurgery and the need for 
further intervention
Variable Mean (standard deviation, range)
Tumor volume at the time of single-fraction radiosurgery 1.3"mL (1.5, 0.03–8.5)
Volume at 3"years after single-fraction radiosurgery (n = 159, 100%) 0.9"mL (1.3, 0.01–10.7)
Volume at 5"years after single-fraction radiosurgery (n = 53, 33.3%) 0.7"mL (1.1, 0.03–6.4)
Volume at >  = 7"years after single-fraction radiosurgery (n = 51, 32.1%) 0.8"mL (0.9, 0.04–5.6)
Further intervention (surgery or single-fraction radiosurgery) 6/159 (3.4%)
Fig. 2  Volume decrease during 
follow-up course at 3, 5, and 
7"years after single-fraction 





sex, Koos grade at the time of SRS, radiation dose rate, 
and the number of isocenters (Table"4).
After adjustment of significant covariates, multivari-
ate model showed that tumor volume decreased in average 
by $ 0.17 (95% CI [$ 0.23, $ 0.11], p < 0.0001) per BED unit 
(Table"4). Moreover, the time point after SRS and the Koos 
grade at the time of treatment moderated the observed 3D 
volumetric change (Table"4).
The dynamics of tumor volume decrease after 
SRS according to the BED value by three catego-
ries 1st, 2nd, and 3rd quartiles can be seen in Fig."3 
(p < 0.0001).
Table 4  Uni- and multivariate analysis
Variable Univariate analysis Multivariate analysis
Coe#cient Beta (Odd’s ratio) p-value Coe#cient Beta (Odd’s ratio) p-value
Changes in volume (as continuous variable) after single-fraction radiosurgery
""Age  $ 0.013 (0.98) 0.09  $ 0.008 (0.992) 0.007
""Sex (male = 0)  $ 0.016 (0.98) 0.9 0.24 (1.27) 0.004
Koos grade (I + II as reference)






""• >  = 7"years
 $ 0.49 (0.61)
 $ 0.54 (0.58)




 $ 1.99 (0.13)
 $ 3.09 (0.04)




BED  $ 0.27 (0.76)  < 0.0001  $ 0.17 (0.84)  < 0.0001
Integral dose received by the tumor volume 0.044 (1.04)  < 0.0001
Radiation dose rate 0.43 (1.53) 0.008
Number of isocenters 0.14 (1.15)  < 0.0001 0.053 (1.05)  < 0.0001
Gradient index  $ 1.77 (0.17)  < 0.0001  $ 0.67 (0.51)  < 0.0001
BED % Koos grade – – 0.11 (1.11) 0.001
BED % Time – – 0.008 (1.008)  < 0.0001
Fig. 3  Volumetric decrease 
during follow-up course at 3, 5, 
and 7"years after single-fraction 
SRS is more important for BED 




Six (3.4%) patients needed further intervention, of whom 
repeat SRS was considered in 2 and planned subtotal 
microsurgical resection followed by SRS in 4. There was 
no statistically significant relationship between the prob-
ability of further intervention and BED (Table"3, p = 0.54), 
although the limited sample size precluded a multivariate 
analysis.
Integral dose received by!the!tumor volume
The integral doses received by the tumor volume were 
inversely correlated with BED. Moreover, oppositely to 
BED, higher integral doses received by the tumor volume 
were associated with VSs increase after SRS (p < 0.0001, 
Fig."4).
Discussion
This retrospective analysis met its primary endpoint and 
showed that BED (ranging between 54.1 and 73.9"Gy) is 
related to volumetric 3D changes after single-fraction, first 
intention SRS for VSs, treated with a uniform radiation 
dose of 12"Gy, for a beam on time varying between 7.3 and 
101.8"min. The overall volumetric changes are supported 
by the durability of responses during a long-term follow-up 
period and can, therefore, be considered long-term con-
trol. Biologically e!ective dose was statistically significant 
both as a continuous value, but also evaluated as 1st, 2nd, 
and 3rd quartiles as related to volumetric changes after 
SRS. The integral dose received by the tumor volume was 
inversely correlated with BED with regard to volumetric 
changes.
The BED is a relatively modern concept, usually 
accounting for the effects of fractionated radiotherapy, 
taking into account the different behaviors of early- and 
late-reacting tissues. In many clinical contexts, radio-
biological considerations can be usefully applied. It has 
been initially defined as the total dose required to give 
the same log cell as the schedule being studied, at an 
infinitely low-dose rate or with infinitely small fractions 
well-spaced out, taking into account the overall time 
factor for repopulation during continued irradiation [6]. 
Thus, clinicians should be aware about developing such 
a quantitative radiobiological approach in their practice 
[11]. In classical radiotherapy, specific attention should 
be given to whether the dose per fraction is being altered, 
possible “hot spots” within the planning, combination 
of treatments, different histological classes for which 
is required a different alpha/beta ratio [11]. Moreover, 
there is a wide expanding use of the BED concept in 
brachytherapy, radiochemotherapy, dose escalation stud-
ies, radionuclide-targeted therapy, or for quantifying any 
treatments using ionizing radiation [6].
Here and to the best of our knowledge, we used 
BED to evaluate volumetric tumor changes after sin-
gle-fraction SRS for benign tumors, such as VSs. It is 
now well acknowledged that beam on time will become 
progressively longer due to the decay of Co-60 sources 
and their half-life of 5.26"years, when using GK for 
SRS. Moreover, even for a fixed source activity, the 
same effect would be attained by plugging/blocking 
beam channels, to protect vital structures, such as the 
cochlea (for hearing preservation in the case of VSs 
treated by SRS) [18], or the optic apparatus (to avoid 
post-SRS optic neuropathy). Additional aspects such 
as collimator factors or inter-patient-specific geometry 
might further influence treatment time, hence the need 
of the BED, incorporating both delivered dose and the 
beam on time.
One of the main strengths of the present study is 
the size of the treated cohort (more than 100 patients), 
treated in a uniform manner, in a single center. Moreo-
ver, all patients have been treated with SRS devices 
that work in an automated manner, with no need 
to account for additional time, such as collimator 
changes, as this could have been the case for former 
GK models (i.e., B, C, etc.). The follow-up period of 
at least 3"years and the durability of the radiologi-
cal response are further key points of such analysis. 
Also, the uniformity of measurements and their slice 
by slice contouring make the reported volumes reliable 
and reproducible.
The limitations of the present study are related to the inher-
ent one pertaining to the retrospective cohorts. Another aspect 
is the use of a simplified BED calculation, using a mono-expo-
nential fit. Yet, our purpose was to provide the reader with 
a clinically relevant analysis with a translational impact. A 
third limitation is that our findings are pertinent only to single-
fraction first intention SRS. In this sense, previously irradiated 
or operated VSs might have a specific and di!erent radiobio-
logical profile.
Conclusions
Overall, the encouraging results obtained here suggest a 
significant relationship between BED and tumor volume 
changes after single-fraction SRS. This could represent a 
potential new treatment paradigm, while aiming at a desired 
radiobiological e!ect and prescribing a certain BED value 
for an individual patient, as modulating the prescribed dose 
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by the factor time. Further studies should validate such an 
approach on larger cohorts.
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